Fentanyl in a pectin gel treating breakthrough pain


  • Borja Mugabure Bujedo, MD
  • Brynjar Karlsson, PhD




fentanyl, breakthrough pain, multiple myeloma, cancer pain


Breakthrough pain (BTP) currently represents a challenge for health professionals dedicated to the treatment of pain. In this descriptive 1-year follow-up study on three patients with BTP from vertebral crush, in the context of multiple myeloma, the authors have observed the great either efficacy or tolerability profile of fentanyl pectin nasal spray. The most relevant findings in this study were better adherence to treatment compared to previously opioids and also great personal satisfaction. Because of common pathophysiological mechanism for noncancerous pain of bone origin, these good results could open the door to investigation of the use of this drug in this patient´s group.

Author Biographies

Borja Mugabure Bujedo, MD

Department of Anesthesiology, Clinical Care and Pain Medicine, University Donostia Hospital, Donostia-San Sebastián, Spain.

Brynjar Karlsson, PhD

Full Professor of Biomedical Engineering, School of Science and Engineering, Reykjavík University, Reykjavík, Iceland.


Breivik H, Collet B, Ventafridda C, et al.: Survey of chronic pain in Europe: Prevalence, impact on daily life and treatment. Eur J Pain. 2006; 10(4): 287-333.

Benzon HT, Connis RT, De Leon-Casasola OA, et al.: Practice guidelines for chronic pain management: An updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010; 112(4): 810-833.

Portenoy R, Hagen N: Breakthrough pain: Definition, prevalence and characteristics. Pain. 1990; 41(3): 273-281.

Hwang SS, Chang VT, Kasimis B: Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003; 101(1-2): 55-64.

Mercadante S, Radbruch L, Caraceni A, et al.: Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002; 94(3): 832-839.

Cánovas Martínez L, Rodríguez A, Castro Bande M, et al.: Treatment of breakthrough pain. Rev Soc Esp Dolor. 2012; 19(6): 318-324.

Fisher A, Watling M, Smith A, et al.: Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100-800 μg in healthy volunteers. Int J Clin Pharmacol Ther. 2010; 48(12): 860-867.

PecFent™: Summary of Product Characteristics (PSPC). Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001164/WC500096493.pdf. Accessed April 29, 2016.

Caraceny A, Martini C, Zecca E, et al.: Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004; 18(3): 177-183.

Portenoy RK, Bennett DS, Rauck R, et al.: Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain. 2006; 7(8): 583-591.

Bennett DS, Simon S, Brennan M, et al.: Prevalence and characteristics of breakthrough pain in patients receiving opioids for chronic back pain in pain specialty clinics. J Opioid Manag. 2007; 3(2): 101-106.

Portenoy RK, Bruns D, Shoemaker B, et al.: Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: Prevalence and characteristics. J Opioid Manag. 2010; 6(2): 97-108.

Portenoy RK, Bruns D, Shoemaker B, et al.: Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: Impact on function, mood, and quality of life. J Opioid Manag. 2010; 6(2): 109-116.

Manchikanti L, Singh V, Caraway DL, et al.: Breakthrough pain in chronic non-cancer pain: Fact, fiction, or abuse. Pain Physician. 2011; 14(2): 103-117.

Vissers D, Stam W, Nolte T, et al.: Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010; 26(5): 1037-1045.

Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.

Zeppetella G, Davies AN: Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 2013;10: CD004311.

Rogríguez D, Urrutia G, Escobar Y, et al.: Efficacy and safety of oral or nasal fentanyl for treatment of breakthrough pain in cancer patients: A systematic review. J Pain Palliat Care Pharmacother. 2015; 29(3): 228-246.

González-Escalada JR, Camba A, Muriel C, et al.: Validation of the Lattinen index for the assessment of chronic pain patients. Rev Soc Esp Dolor. 2012; 19(4): 181-188.

Ruggeri M, Turriziani A, Oradei M: Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain. Expert Rev Pharmacoecon Outcomes Res. 2014; 14(3): 459-464.

Vissers DC, Lenre M, Tolley K, et al. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health. 2011; 14(2): 274-281.

Smith H: Rapid-onset opioids for breakthrough pain. CNS Drugs. 2012; 26(6): 509-535.

Salazar R: 2-Years study to measure the effectiveness of fentanyl pectin intranasal spray in ederly patients with breakthrough noncancer pain. Rev Esp Dolor. 2015; 22(3): 106-111.



How to Cite

Bujedo, MD, B. M., and B. Karlsson, PhD. “Fentanyl in a Pectin Gel Treating Breakthrough Pain”. Journal of Opioid Management, vol. 12, no. 3, May 2016, pp. 197-03, doi:10.5055/jom.2016.0332.